Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 157 clinical trials
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

This phase Ib trial studies the side effects and best dose of navtemadlin when given together with the standard chemotherapy drugs cytarabine and idarubicin in patients with acute myeloid

cytarabine
cancer
gilbert's syndrome
venetoclax
induction chemotherapy
  • 0 views
  • 30 Apr, 2022
  • 2 locations
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

group receive high-dose cytarabine(HDAC) regimen while the experimental group receive high dose of cytarabine plus tretinoin(ATRA) and arsenic trioxide(ATO) treatment.The safety and efficacy of ATRA and

cytarabine
tretinoin
  • 43 views
  • 25 Feb, 2022
  • 1 location
Efficacy and Safety of Chidamide in CBF Leukemia

In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC

cytarabine
  • 35 views
  • 25 Feb, 2022
  • 1 location
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

Rencent years have witnessed great progress of the treatment of acute myeloid leukemia. However, most patients have poor outcomes following the currently first-line DA(daunorubicin, cytarabine

cytarabine
cytarabine/daunorubicin
colony stimulating factor
daunorubicin
azacitidine
  • 0 views
  • 15 May, 2022
  • 1 location
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic

blast crisis
hematopoietic growth factors
chronic myeloid leukemia
venetoclax
cladribine
  • 42 views
  • 17 Mar, 2022
  • 1 location
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

with acute myeloid leukemia. This study involves the following: Venetoclax and azacitidine (investigational combination) Cytarabine and idarubicin or daunorubicin (per

cytarabine
cytarabine/daunorubicin
gilbert's syndrome
venetoclax
azacitidine
  • 0 views
  • 26 Mar, 2022
  • 2 locations
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS

cytarabine
cancer
decitabine
blast cells
myeloid leukemia
  • 12 views
  • 21 Nov, 2021
  • 1 location
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has

serum bilirubin
myelomonocytic leukemia
daunorubicin
serum bilirubin level
leukemia
  • 14 views
  • 26 Jan, 2021
  • 1 location
Blinatumomab Methotrexate Cytarabine and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive or BCR-ABL Positive or Relapsed/Refractory Acute Lymphoblastic Leukemia

This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute

blast crisis
serum bilirubin level
leukemia
lymphoid leukemia
ponatinib
  • 35 views
  • 25 Jan, 2021
  • 2 locations
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

-115 + azacytidine or cytarabine in R/R AML or MDS subjects. Patients will continue treatment for maximally 6 cycles or until progression of disease or unacceptable toxicity is observed or

cytarabine
white blood cell count
cancer
myeloid leukemia
azacitidine
  • 11 views
  • 23 Sep, 2021
  • 10 locations